Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 264

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial

Open access
Yang, Pengfei, Song, Lili, Zhang, Yongwei, Zhang, Xiaoxi, Chen, Xiaoying, Li, Yunke, Sun, Lingli, Wan, Yingfeng, Billot, Laurent, Li, Qiang, Ren, Xinwen, Shen, Hongjian, Zhang, Lei, Li, Zifu, Xing, Pengfei, Zhang, Yongxin, Zhang, Ping, Hua, Weilong, Shen, Fang, Zhou, Yihan, Tian, Bing, Chen, Wenhuo, Han, Hongxing, Zhang, Liyong, Xu, Chenghua, Li, Tong, Peng, Ya, Yue, Xincan, Chen, Shengli, Wen, Changming, Wan, Shu, Yin, Congguo, Wei, Ming, Shu, Hansheng, Nan, Guangxian, Liu, Sheng, Liu, Wenhua, Cai, Yiling, Sui, Yi, Chen, Maohua, Zhou, Yu, Zuo, Qiao, Dai, Dongwei, Zhao, Rui, Li, Qiang, Huang, Qinghai, Xu, Yi, Deng, Benqiang, Wu, Tao, Lu, Jianping, Wang, Xia, Parsons, Mark W, Butcher, Ken, Campbell, Bruce, Robinson, Thompson G, Goyal, Mayank, Dippel, Diederik, Roos, Yvo, Majoie, Charles, Wang, Longde, Wang, Yongjun, Liu, Jianmin, Anderson, Craig S·2022·The Lancet

Abstract

BACKGROUND The optimum systolic blood pressure after endovascular thrombectomy for acute ischaemic stroke is uncertain. We aimed to compare the safety and efficacy of blood pressure lowering treatment according to more intensive versus less intensive treatment targets in patients with elevated blood pressure after reperfusion with endovascular treatment. METHODS We conducted an open-label, blinded-endpoint, randomised controlled trial at 44 tertiary-level hospitals in China. Eligible patients (aged ≥18 years) had persistently elevated systolic blood pressure (≥140 mm Hg for >10 min) following successful reperfusion with endovascular thrombectomy for acute ischaemic stroke from any intracranial large-vessel occlusion. Patients were randomly assigned (1:1, by a central, web-based program with a minimisation algorithm) to more intensive treatment (systolic blood pressure target <120 mm Hg) or less intensive treatment (target 140-180 mm Hg) to be achieved within 1 h and sustained for 72 h. The primary efficacy outcome was functional recovery, assessed according to the distribution in scores on the modified Rankin scale (range 0 [no symptoms] to 6 [death]) at 90 days. Analyses were done according to the modified intention-to-treat principle. Efficacy analyses were performed with proportional odds logistic regression with adjustment for treatment allocation as a fixed effect, site as a random effect, and baseline prognostic factors, and included all randomly assigned patients who provided consent and had available data for the primary outcome. The safety analysis included all randomly assigned patients. The treatment effects were expressed as odds ratios (ORs). This trial is registered at ClinicalTrials.gov, NCT04140110, and the Chinese Clinical Trial Registry, 1900027785; recruitment has stopped at all participating centres. FINDINGS Between July 20, 2020, and March 7, 2022, 821 patients were randomly assigned. The trial was stopped after review of the outcome data on June 22, 2022, due to persistent efficacy and safety concerns. 407 participants were assigned to the more intensive treatment group and 409 to the less intensive treatment group, of whom 404 patients in the more intensive treatment group and 406 patients in the less intensive treatment group had primary outcome data available. The likelihood of poor functional outcome was greater in the more intensive treatment group than the less intensive treatment group (common OR 1·37 [95% CI 1·07-1·76]). Compared with the less intensive treatment group, the more intensive treatment group had more early neurological deterioration (common OR 1·53 [95% 1·18-1·97]) and major disability at 90 days (OR 2·07 [95% CI 1·47-2·93]) but there were no significant differences in symptomatic intracerebral haemorrhage. There were no significant differences in serious adverse events or mortality between groups. INTERPRETATION Intensive control of systolic blood pressure to lower than 120 mm Hg should be avoided to prevent compromising the functional recovery of patients who have received endovascular thrombectomy for acute ischaemic stroke due to intracranial large-vessel occlusion. FUNDING The Shanghai Hospital Development Center; National Health and Medical Research Council of Australia; Medical Research Futures Fund of Australia; China Stroke Prevention; Shanghai Changhai Hospital, Science and Technology Commission of Shanghai Municipality; Takeda China; Hasten Biopharmaceutic; Genesis Medtech; Penumbra.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(22)01882-7

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 264

Metadata

Authors
Yang, P., Song, L., Zhang, Y., Zhang, X., Chen, X., Li, Y., Sun, L., Wan, Y., Billot, L., Li, Q., Ren, X., Shen, H., Zhang, L., Li, Z., Xing, P., Zhang, Y., Zhang, P., Hua, W., Shen, F., Zhou, Y., Tian, B., Chen, W., Han, H., Zhang, L., Xu, C., Li, T., Peng, Y., Yue, X., Chen, S., Wen, C., Wan, S., Yin, C., Wei, M., Shu, H., Nan, G., Liu, S., Liu, W., Cai, Y., Sui, Y., Chen, M., Zhou, Y., Zuo, Q., Dai, D., Zhao, R., Li, Q., Huang, Q., Xu, Y., Deng, B., Wu, T., Lu, J., Wang, X., Parsons, M. W., Butcher, K., Campbell, B., Robinson, T. G., Goyal, M., Dippel, D., Roos, Y., Majoie, C., Wang, L., Wang, Y., Liu, J., & Anderson, C. S.
Venue
The Lancet
Publisher
Elsevier BV
Published
2022-11
Volume
400
Issue
10363
Pages
1585-1596
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4307728974
Cited by
264
References
26
FWCI
30.01
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(22)01882-7
The paper
Yang, P., Song, L., Zhang, Y., Zhang, X., Chen, X., Li, Y., Sun, L., Wan, Y., Billot, L., Li, Q., Ren, X., Shen, H., Zhang, L., Li, Z., Xing, P., Zhang, Y., Zhang, P., Hua, W., Shen, F., . . . Anderson, C. S. (2022). Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(22)01882-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.